Retatrutide: the next generation of weight-loss medication
Retatrutide targets three hormone receptors — GLP-1, GIP, and glucagon — and has produced the largest average weight loss reported in clinical trials so far. It is not yet FDA-approved. We follow the research closely and will discuss eligibility and availability with you as it becomes an approved option.
What makes retatrutide different
Adding glucagon receptor activity to the GIP/GLP-1 combination appears to increase energy expenditure alongside appetite control. In the Phase 3 TRIUMPH-1 trial, participants on the highest dose lost an average of about 28% of their body weight over 80 weeks.
Where it stands
Retatrutide is in late-stage clinical development by Eli Lilly and has not been approved by the FDA. Products marketed as retatrutide today are not approved medications, and Reset You MD does not recommend obtaining them outside of a clinical trial or an FDA-approved supply. We update this page as the regulatory picture changes.
What you can do now
- Book a consultation to review whether semaglutide or tirzepatide is right for you today
- Start the labs, body-composition baseline, and nutrition plan that any medication works best with
- Ask us to keep you informed about retatrutide approval and eligibility
Retatrutide FAQ
Can I get retatrutide at Reset You MD now?
Not until it is FDA-approved and available through a legitimate supply. In the meantime, tirzepatide and semaglutide are proven, physician-supervised options.
When might it be approved?
Timelines depend on FDA review of the Phase 3 program. We'll share updates as they're announced.
Ready to talk about Retatrutide?
Book a complimentary consultation — we'll review your goals and history and map out whether this is the right next step.
THE PATIENT AND ANY OTHER PERSON RESPONSIBLE FOR PAYMENT HAS A RIGHT TO REFUSE TO PAY, CANCEL PAYMENT, OR BE REIMBURSED FOR PAYMENT FOR ANY OTHER SERVICE, EXAMINATION, OR TREATMENT THAT IS PERFORMED AS A RESULT OF AND WITHIN 72 HOURS OF RESPONDING TO THE ADVERTISEMENT FOR THE FREE, DISCOUNTED FEE, OR REDUCED FEE SERVICE, EXAMINATION, OR TREATMENT.